Top

Globalization and Health

Published in:

Open Access 01-12-2020 | Public Health | Research

Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market

Authors: Tatiana Dănescu, Maria-Alexandra Popa

Published in: Globalization and Health | Issue 1/2020

Abstract

Background

Corporate social responsibility (CSR) is studied from many perspectives and has gained unprecedented importance in recent years, especially in emerging economies. Pharmaceutical companies play a very important role in a population’s well-being and health through the CSR and corporate governance practices that they apply.

Methods

We used an exploratory approach to measure compliance with the Corporate Governance Code of pharmaceutical companies listed on the Romanian capital market and with practices declared through CSR.

Results

The results show that pharmaceutical companies are involved in actions that consider the well-being of society by offering financial support and managing various sustainable projects, targeting social and economic issues, leading public health awareness campaigns, and investing in health projects.

Conclusion

This study highlights the increasingly important role played by corporate governance and corporate social responsibility in pharmaceutical companies in improving public health in countries with emerging economies.

Leonard D, McAdam R. Corporate social responsibility. Qual Prog. 2003:27–32.

Lee N, Kotler P. Corporate social responsibility doing the most good for your company and your cause. Hoboken: Wiley; 2013. ISBN 978-1118045770.

Fooks G, Gilmore A, Collin J, Holden C, Lee K. The limits of corporate social responsibility: techniques of neutralization, stakeholder management and political CSR. J Bus Ethics. 2013;112:283–99. https://doi.org/10.1007/s10551-012-1250-5.CrossRefPubMed

Hastings G. Why corporate power is a public health priority. BMJ. 2012;345:e5124. https://doi.org/10.1136/bmj.e5124.CrossRefPubMed

Margolis, J. D., & Walsh, J. P. (2003). Misery loves companies: rethinking social initiatives by business. Admin Sci Q, 48(2), pp. 268. doi: https://doi.org/10.2307/3556659.

Walsh JP. Book review essay: taking stock of stakeholder management. Acad Manag Rev. 2005;30:426–52.CrossRef

Leisinger K, M. The corporate social responsibility of the pharmaceutical industry: idealism without illusion and realism without resignation. Bus Ethics Q. 2005;15:577–94 https://doi.org/10.1017/S1052150X00007855.CrossRef

Tăchiciu L, Fülöp MT, Marin-Pantelescu A, Oncioiu I, Topor DI. Non-financial reporting and reputational risk in the Romanian financial sector. Amfiteatru Econ. 2020;22(55):668–91.

Moon S. Respecting the right to access to medicines: implications of the UN guiding principles on business and human rights for the pharmaceutical industry. Health Hum Rights. 2013;15(1):32–43.

10.

Hunt P, Khosla R. Are drug companies living up to their human rights responsibilities? The perspective of the former United Nations special rapporteur (2002-2008). PLoS Med. 2010;7(9):e1000330.CrossRef

11.

International Consumers. (2006). Branding the cure: a perspective on corporate social responsibility, drug promotion and the pharmaceutical industry in Europe, ISBN: 1–902391–69-1, London.

12.

Demir M, Min M. Consistencies and discrepancies in corporate social responsibility reporting in the pharmaceutical industry. Sustain Account Manage Policy J. 2019;10(2):333–64. https://doi.org/10.1108/SAMPJ-03-2018-0094.CrossRef

13.

Frederiksen T. Political settlements, the mining industry and corporate social responsibility in developing countries. Extract Indust Soc. 2018. https://doi.org/10.1016/j.exis.2018.07.007.

14.

McLennan S, Banks G. Reversing the lens: why corporate social responsibility is not community development. Corp Soc Responsib Environ Manag. 2018. https://doi.org/10.1003/crs.1664.

15.

Banerjee SB. Corporate social responsibility: the good, the bad and the ugly. Crit Sociol. 2012;34(1):51–79. https://doi.org/10.1177/0896920507084623.CrossRef

16.

Droppert H, Bennett S. Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms. Glob Health. 2015;11(1). https://doi.org/10.1186/s12992-015-0100-5.

17.

Lee J-Y, Hunt P. Human rights responsibilities of pharmaceutical companies in relation to access to medicines. J Law Med Ethics. 2012;40:220–33.CrossRef

18.

Ritter GS. Are drug companies living up to their human rights responsibilities? The merck perspective. PLoS Med. 2010;7:e1000343.CrossRef

19.

Vian T, McCoy K, Richards SC, Connelly P, Feeley F. Corporate social responsibility in global health: the Pfizer Global Health fellows international volunteering program. Hum Resour Plan J. 2007;30:30–5.

20.

Haro-de-Rosario A, Saraite L, Mar Gálvez-Rodríguez M, Del Carmen Caba-Pérez M. La industria farmaceutica ante la demanda de responsabilidad social corporative. Rev Perspect Empres. 2016;3(1):55.CrossRef

21.

Money K, Schepers H. Are CSR and corporate governance converging? A view from boardroom directors and company secretaries in FTSE 100 companies in the UK. J Gen Manag. 2007;33(2):1–11.

22.

Bondy K, Matten D, Moon J. Multinational corporation codes of conduct: governance tools for corporate social responsibility? Corp Gover Int Rev. 2008;16(4):294–311. https://doi.org/10.1111/j.1467-8683.2008.00694.x.CrossRef

23.

Flammer C, Hong B, Minor D. Corporate governance and the rise of integrating corporate social responsibility criteria in executive compensation: effectiveness and implications for firm outcomes. Strateg Manag J. 2019. https://doi.org/10.1002/smj.3018.

24.

Shin H-D, Lee NR, Park JH. Differential Effects of Strong Corporate Governance on Both Professional and Voluntary Corporate Social Responsibility Activities of the Firm. Emerg Markets Finance Trade. 2015;51(sup4):S2–S10. https://doi.org/10.1080/1540496X.2014.1013860.CrossRef

25.

Barnett M, Salomon R. Does it pay to be really good? Addressing the shape of the relationship between social and financial performance. Strateg Manage J. 2011;33. https://doi.org/10.2307/41679849.

26.

Frynas JG, Mahmood Z. Determinants of corporate social responsibility (CSR) disclosure in developed and developing countries: a literature review. Corp Soc Responsib Environ Manag. 2017;24(4):273–94. https://doi.org/10.1002/csr.1410.CrossRef

27.

Fombrun CJ, Gardberg NA, Sever JM. The reputation Quotinet SM: a multi-stakeholder measure of corporate reputation. J Brand Manage. 2013:241–55.

28.

Godfrey PC, Merrill CB, Hansen JM. The relationship between corporate social responsibility and shareholder value: an empirical test of the risk management hypothesis. Strateg Manag J. 2009;30(4):425–45. https://doi.org/10.1002/smj.750.CrossRef

29.

Godfrey PC. The relationship between corporate philanthropy and shareholder wealth: a risk management perspective. Acad Manag Rev. 2005;30(4):777–98.CrossRef

30.

Barnett M. Stakeholder influence capacity and the variability of financial returns to corporate social responsibility. Acad Manag Rev. 2007;32(3):794–815.CrossRef

31.

Min M, Desmoulins-Lebeault F, Esposito M. Should pharmaceutical companies engage in corporate social responsibility? J Manage Dev. 2017;36:58–70. https://doi.org/10.1108/jmd-09-2014-0103.CrossRef

32.

Comes C-A, Bunduchi E, Vasile V, Ștefan D. The impact of foreign direct investments and remittances on economic growth: a case study in central and Eastern Europe. Sustainability. 2018;10(1):238. https://doi.org/10.3390/su10010238.CrossRef

33.

Vasile V, Bunduchi E, Daniel Ş, Comes CA. Impact of remittances on the country of origin. Multidimensional analysis at macro and microeconomic level. Case study Romania and Moldova. Romanian Statistical Review. 2019;4:3–22.

34.

Svejnar J. Transition economies: performance and challenges. J Econ Perspect. 2002;16(1):3–28. https://doi.org/10.1257/0895330027058.CrossRef

35.

Peters S, Miller M, Kusyk S. How relevant is corporate governance and corporate social responsibility in emerging markets? Corp Gover Int J Bus Soc. 2011;11(4):429–45. https://doi.org/10.1108/14720701111159262.CrossRef

36.

World Economic Forum (2018). The Inclusive Development Index 2018 Report, Available at: http://www3.weforum.org/docs/WEF_Forum_IncGrwth_2018.pdf.

37.

Institute of Economic Forecasting (2012). Industria farmaceutică din România: principalele tendințe și impactul asupra societății și economiei, Available at: http://www.lawg.ro/files/assets/userfiles/files/Industria%20Farmaceutica%20din%20Romania.pdf.

38.

Bucharest Stock Exchange: https://www.bvb.ro/forcompanies/mainmarket/issuingshares#l3.

39.

Bucharest Stock Exchange (2015). Corporate Governance Code, Available at: https://www.bvb.ro/info/Rapoarte/Diverse/RO_Cod%20Guvernanta%20Corporativa_WEB_revised.pdf.

40.

Directive 2014/95/EU of the European Parliament and of the Council of 22 October 2014 amending Directive 2013/34/EU as regards disclosure of non-financial and diversity information by certain large undertakings and groups Text with EEA relevance.

41.

Ministry of Public Finance, Order No. 1938/2016 Regarding the Modification and Completion of Some Accounting Regulations, Published In: Official Monitor No. 680 in September 2, 2016.

42.

Ministry of Public Finance, Order No. 2844/2016 of December 12, 2016 for the Approval of the Accounting Regulations in Accordance with the International Financial Reporting Standards, Published In: Official Monitor No. 1020 in December 19, 2016.

43.

Popa, M.A. & Dănescu, T. (2020). Corporate Social Responsibility and Public Health-Pharmaceutical Companies in an emerging market. doi: https://doi.org/10.17605/OSF.IO/NFZ65.

Title: Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market
Authors: Tatiana Dănescu
Maria-Alexandra Popa
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Public Health
Published in: Globalization and Health / Issue 1/2020
Electronic ISSN: 1744-8603
DOI: https://doi.org/10.1186/s12992-020-00646-4

At a glance: The STEP trials

Springer Medicine

Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Leaving no one behind: lessons from implementation of policies for universal HIV treatment to universal health coverage

Impact of international travel dynamics on domestic spread of 2019-nCoV in India: origin-based risk assessment in importation of infected travelers

Medical education: an Italian contribution to the discussion on global health education

HIV/AIDS research in Africa and the Middle East: participation and equity in North-South collaborations and relationships

Beyond the healthy immigrant paradox: decomposing differences in birthweight among immigrants in Spain

Heat-health vulnerability in temperate climates: lessons and response options from Ireland